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Abstract The increased use of opioids for chronic treatment
of pain and the resulting epidemic of opioid overdoses have
created a major public health challenge. Parenteral naloxone
has been used since the 1970’s to treat opioid overdose.
Recently, a novel naloxone auto-injector device (EVZIO,
kaleo, Inc., Richmond, VA) was approved by the Food and
Drug Administration. In this article, we review the Human
Factors Engineering (HFE) process used in the development
and testing of this novel naloxone auto-injector currently used
in nonmedical settings for the emergency treatment of known
or suspected opioid overdose. HFE methods were employed
throughout the product development process for the naloxone
auto-injector including formative and summative studies in
order to optimize the auto-injector’s user interface, mitigate
use-related hazards and increase reliability during an opioid
emergency use scenario. HFE was also used to optimize the
product’s design and user interface in order to reduce or pre-
vent user confusion and misuse. The naloxone auto-injector
went through a rigorousHFE process that included perceptual,
cognitive, and physical action analysis; formative usability
evaluations; use error analysis and summative design valida-
tion studies. Applying HFE resulted in the development of a
product that is safe, fast, easy and predictably reliable to de-
liver a potentially life-saving dose of naloxone during an opi-
oid overdose emergency. The naloxone auto-injector may be
considered as a universal precaution option for at-risk patients
prescribed opioids or those who are at increased risk for an
opioid overdose emergency.
Keywords Naloxone . Auto-injector . Opioid overdose .
Human factors engineering . Opioid-induced respiratory
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Introduction
Increasing awareness of the mechanisms of pain in humans
and an ethical obligation to provide greater pain control [1]
have driven increased prescribing of opioids. From 1991 to
2013, the number of prescriptions for opioids have increased
from approximately 76 million to 207 million in the United
States [2]. Drug poisoning deaths attributable to opioid anal-
gesics quadrupled from about 4000 in 1999 to over 16,000 in
2010 [3]. In 2014, there were 18,893 fatalities from prescrip-
tion opioid overdoses. The vast majority (83 %) of fatalities
are unintentional [4, 5]. Moreover, opioid deaths now exceed
the number of deaths for both suicide and motor vehicle acci-
dents combined [6]. In a study of unintentional overdoses in
West Virginia from 1999 to 2004, opioid analgesics were tak-
en by 93 % of decedents, but only 44 % had prescriptions for
those drugs [7]. The majority of opioid-associated uninten-
tional deaths (60 %) occur in patients prescribed opioids ac-
cording to current prescribing guidelines [6], are prescribed
opioids by a single practitioner [8], and do not have a
substance-abuse disorder diagnosis [9]. Themajority of opioid
overdose deaths occur at home and are witnessed, including
deaths associated with prescribed opioids [10]. In 2010, a total
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of 135,971 visits to US emergency departments occurred for
opioid overdose, but this represents only a fraction of the total
number of opioid overdoses as many individuals do not pres-
ent to the emergency department or die before reaching emer-
gency care [11]. This epidemic of opioid overdose also im-
pacts children in the US as, on average, approximately 3300
children ≤5 years old are admitted to emergency departments
each year due to opioid exposure and poisonings [12].
During opioid-induced respiratory depression (OIRD)
resulting from an opioid overdose, brain cells are starved of
oxygen and start to die within about four minutes, which in
many situations is much sooner than the average emergency
response time (approximately 9 min) [13–15]. Thus, there is a
clear need for an opioid overdose antidote that is designed and
intended to specifically be used by laypersons, with or without
training, outside of a healthcare setting.
Naloxone hydrochloride, an opioid antagonist, was initially
approved by the US Food and Drug Administration (FDA) in
1971 as an emergency medication indicated for the diagnosis
or treatment of suspected opioid overdose [16]. Naloxone is
generally administered intravenously, intramuscular or subcu-
taneously due to its low bioavailability via oral routes and high
1st pass metabolism [17]. Naloxone also rapidly crosses the
blood brain barrier due to its high lipophilicity [17]. Once in
the central and peripheral nervous system, naloxone exerts its
function by altering the binding affinity and ligand-receptor
binding kinetics of many opioids as well as receptor messag-
ing [17]. Clinical use of naloxone grew rapidly due to a num-
ber of key properties, which include strong affinity for the μ-
receptor, rapid reversal of central and peripheral effects of
opioids, minimal side effects at doses 100-fold above thera-
peutic levels and its inability to produce respiratory depression
[17]. Naloxone hydrochloride became the standard of care for
treating life-threatening OIRD [18]. Due to differences in opi-
oids, repeated naloxone doses may need to be administered to
reverse OIRD or central nervous system (CNS) depression
emergencies. There are no contraindications to naloxone hy-
drochloride other than hypersensitivity to naloxone or to any
of the ingredients in the formulation. Injectable naloxone may
be administered to pediatrics, including neonates, and during
pregnancy when the potential benefits outweigh the risks.
Administration of naloxone to reverse life-threatening opi-
oid-related respiratory depression may cause a sudden and
complete reversal of opioid effects and precipitate withdrawal
symptoms including irritability, confusion, or nervousness.
Previously, there were no FDA approved stand-alone nal-
oxone prescription products on the market specifically labeled
for use in non-medical settings such as the home and by non-
medical personnel, including caregivers or family members of
patients. Until recently, only three realistic scenarios existed in
which an individual in the community setting might receive
naloxone during a suspected opioid emergency: (1) the nalox-
one is administered by an emergency responder, (2) the patient
is taken to the hospital where naloxone is administered in the
hospital emergency department, or (3) naloxone is adminis-
tered using a naloxone kit from a harm reduction program
[19]. Administering emergency naloxone from a naloxone
kit requires the user to be familiar with the products and proper
administration technique, including being able to draw the
correct dose from a vial into a syringe or assembling an im-
provised multi-component injectable naloxone system
adapted for intranasal (IN) delivery, and then properly admin-
istering the dose(s) to the patient [20]. Since emergency nal-
oxone is by definition administered in high-stress emergency
situations, untrained bystanders may feel overwhelmed by
these requirements. Furthermore, the unprotected needles in
some of these systems could unnecessarily expose the indi-
vidual who is administering the naloxone to the patient to
blood-borne pathogens.
Effective use of naloxone for opioid overdose populations
has been demonstrated in community-based distribution pro-
grams. In a study of 2500 subjects from 2010 to 2013, nalox-
one distribution resulted in 702 opioid reversals and the nal-
oxone refills were most likely obtained by those who had
witnessed an overdose and those who used heroin or metham-
phetamine [21]. An overdose education and naloxone distri-
bution (OEND) program implemented in 19 New England
communities reported training of 2912 potential bystanders
and a total of 327 rescues [22]. Other community-based over-
dose prevention programs (OPPs), such as Project Lazarus,
have been similarly effective in preventing and reversing po-
tentially life-threatening opioid overdoses [23, 24]. Thus,
structured programs offering access and training for prompt
and appropriate administration of naloxone are a life-saving,
effective strategy to help reduce opioid-related deaths.
Most of the aforementioned community-based programs
utilize kits consisting of injectable naloxone adapted for IN
delivery with a mucosal atomizer device. These IN naloxone
delivery systems have been studied for reversing opioid-over-
dose [25]. The nasal mucosa is richly supplied with blood
vessels and, in individuals who do not have underlying nasal
disease or who have not recently used a vasoconstrictor, this
may allow for rapid and adequate drug absorption. For exam-
ple, in two randomized controlled clinical studies, IN nalox-
one was able to reverse OIRD in 74% and 72% of cases [25].
However, patients who received intramuscular (IM) naloxone
responded more quickly than patients who received IN nalox-
one in terms of increased breaths per minute and two to four
times as many IN reversals required supplementary naloxone
compared to IM reversals [26, 27].
The distribution focus for IN naloxone has been heroin
users, although patients taking opioids under medical super-
vision for chronic or cancer pain, as well as children in these
households, actually comprise the larger population at risk for
opioid emergencies [28]. Non-clinicians must be trained to
administer naloxone properly as improper technique or dosing
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during an opioid emergency may result in incomplete opioid
overdose reversal. Recently, a CDC report highlighted that
additional models for distribution of naloxone to persons
who might witness prescription opioid overdoses are needed
[29]. With the available naloxone product limitations and the
apparent need for additional naloxone distribution models, a
novel naloxone auto-injector (EVZIO, kaleo, Inc., Richmond,
VA) was designed and developed using human factors engi-
neering (HFE) methods and guidelines. The auto-injector was
developed as a Btake-home^ naloxone formulation that could
be used outside of traditional healthcare settings by untrained
individuals who are most likely to witness an opioid overdose
emergency. The device is designed for only one injection,
which provides a single therapeutic dose of 0.4 mg naloxone
(recommended range is 0.04 mg to 2 mg) for reversing opioid
overdose [17]. In addition, the single use design with audible
prompts is a very important safety feature, which acts as an
abuse deterrent and prevents repurposing the device with an-
other syringe or injection device, prevents needle sharing use
on another person, allows user to know exactly when the
device has delivered a dose and when device is empty, and
allows user to control dose and reduce likelihood of precipi-
tating opioid withdrawal symptoms.
Methods
In the sphere of medical devices, HFE applies knowledge
about human capabilities and limitations to the appropriate
design and development of the device [30, 31]. HFE deter-
mines how andwhen a device would be used and how humans
will interact with the device, seeking to minimize difficulties
and pitfalls and optimize the likelihood of successful device
use outcomes for the patient and end user. Thus, HFE may
affect product design (e.g., buttons, covers, casings, alarms,
labeling) to allow for optimal use and appropriate device func-
tion. This may include designing a product that allows for
human limitations (such as poor eyesight, limited manual dex-
terity) as well as environmental conditions (e.g., lighting,
stress, noise). The FDA recommends that HFE be applied
early in the design process to allow for the most efficient,
streamlined, and optimal product design possible, ensuring
safe and effective use by mitigating or eliminating use-
related hazards [31, 32]. HFE has been employed to optimize
other similar devices for use by the general public, such as
epinephrine auto-injectors [33].
Expanding access to naloxone for high-risk individuals and
those around them is a key component of opioid harm reduc-
tion initiatives [34]. Any naloxone product must be designed
to allow for rapid, accurate, and effective administration, thus
human factors engineers played a critical role in the design of
a novel take-home naloxone auto-injector intended for use by
caregivers, family members, or other laypeople. The design of
EVZIO (naloxone hydrochloride injection) auto-injector was
based on best practices in incorporating human factors analy-
ses and rigorous verification and validation testing throughout
the development process. Since this product is subject to use
in an emergency situation by a diverse group of people with
varying levels of skills and abilities, it was essential to create a
product that is safe and easy to use, even for a person with no
prior training or exposure to the product. Development activ-
ities were guided by the Quality System Regulation’s Design
Controls phases as contained in the Code of Federal
Regulations, part 820.30 as well as FDA Guidance on the
application Human Factors Engineering [31]. An iterative de-
sign philosophy was employed, encompassing the steps of
research, design, risk assessment, review, and testing that then
led to redesign, review, and further testing until the various
potential hazards of the product could be mitigated to an ac-
ceptable level (Table 1).
The primary tasks associated with a successful injection
using the naloxone auto-injector involve: 1) removing the out-
er case, 2) removing the safety guard, 3) placing the black
(needle) end of the device on the outer thigh, 4) activating
the device and holding it in place for at least 0.5 s. Use-
related hazards were evaluated during the development of this
device by using several human factors methodologies includ-
ing functional decomposition, formative usability evaluations,
expert reviews, and heuristic analyses. Risks identified (e.g.,
user must understand quickly and accurately how to give the
injection) during these steps shaped the final design of the
auto-injector including device and outer case labeling.
The auto-injector
HFE and usability engineering processes were used to create a
device that is portable (dimensions are approximately credit-
card size with the thickness of a smartphone), ambidextrous in
design, easy to handle, and use safely and effectively in almost
any use environment during a suspected opioid emergency.
The auto-injector’s slim size allows it to be easily grasped
by people with various hand sizes, including children, and
allows for proper injection orientation. The outer case and
device housing was built for durability with robust materials,
providing impact resistance for the product. It contains a view-
ing window so that the user can readily confirm drug contents
and use status (contents are clear prior to use and the window
is obstructed following use). See Figs. 1 and 2. The needle in
the naloxone auto-injector is shielded by a red safety guard
that alerts the user to the location of the needle (red color
implying a hazard) and provides instructions on how to re-
move the guard, which has tactile features to assure that it can
be easily gripped and pulled off. The guard is designed in such
a way that a degree of appropriate force is required to remove
it, in order to ensure that the guard remains in place until the
device is ready to be used. A sharps-injury prevention feature
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(retractable needle) was built into the device to assure the user
never sees the needle before, during, or after naloxone admin-
istration thereby helping to also prevent inadvertent needle
sticks post-injection. A naloxone formulation was specifically
developed based upon the proven injectable formulation and
tested, along with a new glass cartridge and elastomeric con-
tainer closure system, to withstand temperature extremes up to
104 degrees for six months while maintaining naloxone
stability.
Feedback from patients using opioids and their caregivers
was utilized in order to optimize the labeling interface for the
device, including the arrows, text placement, symbols,
graphics, instructions found on the device, and on the
Instructions for Use leaflet that accompanies the product.
The largest possible font size and appropriate symbols were
chosen to make the instructions as clear as possible without
compromising regulatory labeling requirements. The auto-
injector also offers redundancy in its instruction system by
incorporating an innovative and smart electronic prompt sys-
tem (the Intelliject Prompt System IPS®) that provides audi-
ble instructions for use from a speaker as well as visual cues in
the form of LEDs in order to assist in guiding a user through
the injection process. No special user activation is required for
the audible prompts, which are automatically turned on and
off by removing or replacing the outer case and advance with
the user tasks at the user’s pace, repeating if necessary. The
prompts were carefully scripted to allow for quick, clear step-
by-step actions in the case of an emergency and are delivered
in a reassuring female voice. An acoustic chamber enhances
the volume of the voice commands. The audible prompts tell
the user what to do at each step and will repeat instructions if
the user omits a critical step. When the injection is being
Table 1 The naloxone auto-
injector’s verification and
validation test plan included
testing associated and in
compliance with FDA Guidance
as well as the International
Organization for Standardization
(ISO): ISO 11608–1:2012, ISO
11608–2:2012, and ISO 11608–
3:2012; other standard bodies
such as UL, ASTM, and ISTA. In
addition, tests were selected based
on risk analyses. The following
table provides a brief description
of each test as well as its
associated reference(s). This
listing of tests is not a
comprehensive list of all testing
conducted for the naloxone auto-
injector
Description References
Dose Accuracy Test ISO 11608–1
Environmental Exposure Test ISO 11608–1
Section 9.2.2
Pre-Conditioning Test ISO 11608–1
IEC 60068–2-30
IEC 60068–2-6
IEC Testing ISO 11608–1 (Section 10 and 11)
UL/IEC 60601–1-1
IEC 60601–1-2
Needle Bond Strength Test Method ISO 11608–2 (Section 11)
IEC 60068–2-30
Freedom From Leakage Test ISO 11608–3, Section 5.5.
Plunger Break/Glide Force Test ISO 11608–3
Section 5.6
Lock Out and Crush Test FDA Draft Guidance on Injectors
Injection Through Material Test User FMEA
Force to Remove Safety Guard FDA Draft Guidance on Injectors
Activation Force Test DFMEA
Battery Life Testing User FMEA
Sound Level Testing User FMEA
Device Accelerated Age Testing ISO 11608,Medical Plastics and Biomaterials, July/August 1998.
Pp. 16–23
Safe Transit, Distribution, and Shipping
Testing
ISTA Guidelines ASTM D4169–08
Device Biocompatibility Testing ISO 10993
Altitude Function Test FDA Draft Guidance on Injectors
Exposed Needle Length Test ISO 11608
Label Wear Test User FMEA
Liquid Ingress Test IEC 60529
Dispensing Time Test DFMEA
Retraction Occurrence & Visual
Inspection
ISO 11608–1
user fmea: user failure mode and effects analysis, dfmea: design failure mode and effects analysis
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administered, the device provides an audible countdown (e.g.
5, 4, 3, 2, 1) to help users hold the device in place to ensure
complete naloxone delivery. When the injection is complete,
the audible prompts confirm injection and remind the user to
seek emergency medical attention. Post-use indicators tell the
user that the device is used and should be properly discarded
(Table 1).
Training & User Populations
OIRD can develop gradually or suddenly into a life-
threatening emergency which may be fatal in a matter of mi-
nutes. During this situation an individual equipped with nal-
oxone can use the product to quickly deliver a potentially life-
saving dose of parenteral naloxone. The naloxone auto-
injector includes labeling on the device itself as well as an
accompanying User Information leaflet. Moreover, a trainer
device is included in each package so that a new user can
practice the proper steps for using the auto-injector and train
others on how to properly administer the product given that
most patients are unresponsive during an opioid emergency
requiring intervention from another individual such as a fam-
ily member or other caregiver. The trainer for practice is similar
in look and feel to the actual auto-injector device but does not
contain a needle, the drug, or the activation mechanism for drug
delivery. However, the trainer allows the user to practice the
primary use tasks including removal of the outer case, the red
safety guard, actuation of the black base, and become familiar
with the audible prompts. In addition, the forces in the trainer
were designed to mimic the forces used in the actual device in
order to further facilitate correct use (e.g. safety guard removal
force). The batteries in the trainer allow for repeated use once per
day for several years if required. Of course, it is possible that
situations could arise in which an individual with little or no
training might have to use the auto-injector. For that reason the
device and its user interface were specifically designed, validat-
ed, and approved to be used quickly by laypersons even without
training.
Fig. 1 EVZIO (naloxone hydrochloride injection) Auto-injector Human Factors Development Plan
Fig. 2 The naloxone auto-injector is provided in a removable outer case.
To increase performance success and decrease cognitive demand, the
motion to slide off the outer case is in the same direction as the motion
needed to pull off the safety guard. Once the outer case is removed, a
removable red plastic safety guard shields the needle. A tactile design
allows the safety guard to be gripped and pulled off when needed during
an emergency. The outer case and the auto-injector have a viewing win-
dow to inspect the naloxone and to assess if the auto-injector has been
used. The auto-injector also includes an electronic prompt system that
provides voice instructions from a speaker and visual cues from LEDs
to assist in guiding the user through the injection
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There are three main types of users of Btake-home^ nalox-
one. The first are caregivers to patients at increased risk for an
opioid overdose emergency; these caregivers would be most
likely to witness an opioid emergency in a home setting.
While caregivers should be trained in the use of a naloxone
product, it is nevertheless possible that an untrained family
member might have to deliver the naloxone dose. A key con-
cern in this scenario is that family members need to be able to
locate the naloxone product quickly and use it correctly during
an emergency. The next scenario involves a secondary care-
giver, such as a coworker or friend. Ideally, secondary care-
givers would receive training, but this may not always be the
case; secondary caregivers may be more prone to getting flus-
tered or overwhelmed by the emergency situation than prima-
ry caregivers. As a result, a product must be readily available
and easy to understand, even if the user has not been trained
recently or not trained at all. The third scenario involves a
layperson who encounters a potential opioid overdose and is
able to rapidly assess and respond to the emergency. If the
layperson is a peer or drug user, he or she may have naloxone
available or know to search for a naloxone product on the
person. If the layperson is a random bystander, much depends
on his or her ability to interpret the situation and search for the
naloxone product. In the latter scenario, the layperson may fail
to know about naloxone, and even if finding a product, may
panic and not comprehend its use. However, for each of the
above scenarios the naloxone auto-injector was specifically
designed to be portable so that the product would be available
on the patient or readily available for a caregiver in case of an
opioid overdose emergency, and intuitive so that even if an
untrained person finds the auto-injector, he or she would be
able to use it properly and quickly. In addition, each naloxone
auto-injector carton comes with two active devices so that
multiple doses are available if required. The naloxone auto-
injector can be used at most locations including home, work,
restaurants, bars, outdoors, schools, on airplanes or other
modes of transportation, at public gatherings such as concerts,
and in places of entertainment. The naloxone auto-injector is
not suitable for use in extreme environments, such as under-
water or when exposed to extremely hot or cold temperatures
for extended periods of time.
Potential use errors and mitigation
With any such product, especially in the case of products
intended for administration during life-threatening emergen-
cies, there is a hierarchy of use errors that range from critical
(errors which could lead to a person not receiving a potentially
life-saving dose of naloxone) to moderate (errors which could
lead to a person possibly receiving an ineffective dose of nal-
oxone or a significant delay in receiving naloxone) to minor
(errors which might cause user frustration or a slight delay in
administering naloxone). Conducting a thorough use risk
assessment is an essential part of applying HFE to medical
products and to obtaining FDA approval [31]. Potential use
errors identified as a part of risk analyses conducted with the
naloxone auto-injector have been summarized and catego-
rized (Table 2).
As a part of developing the naloxone auto-injector using
HFE, steps were taken to mitigate these aforementioned use-
related risks. For example, the naloxone injection is adminis-
tered in less than 0.5 s, although product labeling and voice
prompts require that the auto-injector be held in place for five
seconds. The reason for this difference is that in emergency
situations, users may panic and not hold the device in place
long enough without a count-down that exceeds the injection
time. The extra time the auto-injector is held in place does no
harm and assures the dose is fully administered with complete
needle retraction. As another example, the device and its outer
case were designed with robust materials to be crush-resistant.
This ensures that even if the product is dropped while being
carried or the product is exposed to forces (e.g. sitting on the
device) it will still function as intended.
The auto-injector specifies in labeling and in graphics that
the injection is to be administered to the outer thigh and may
be delivered through clothing. The outer thigh is an ideal
injection site, but any number of other muscular locations
(e.g., leg, upper arm, shoulder) would also be appropriate.
This information is not provided on the device in an effort to
streamline instructions and keep the use instructions simple
during a highly stressful situation.
Results: user-needs evaluations and randomized,
controlled usability studies
Initial user-needs evaluation
Nine adult caregivers (ranging in age from 32 to 66 years)
were asked to use a prototype of the auto-injector device
(without needle or drug) to inject an orange without any train-
ing as to how to use the product. As expected, use errors
occurred on the prototype device as several users struggled
to figure out how to remove the outer case or pull off the red
safety guard. This feedback helped to refine final product
design, labeling and the Instructions for Use. All (100 %)
participants in this study believed the product was easy to
use, and thought it was important to have, even if they did
not think the patients they cared for were at high risk for
opioid overdose. Additionally, all participants said the audible
prompts were helpful.
Labeling evaluation
Seven current opioid patients and seven caregivers (n = 14)
evaluated the auto-injector design and instructions.
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Participants were provided various labeling designs and
given randomized levels of training (ranging from no
training at all to full training including review of the
Instructions for Use leaflet). Subjects ranged in age
from 30 to 65 years. All 14 participants were asked to
simulate an injection into a mannequin; 100 % could do
so successfully. It should be noted that 2/14 participants
had a close call in completing the tasks correctly but
adjusted their actions based on voice prompts and com-
pleted the injection properly. All participants rated use
as Bcompletely easy,^ Beasy,^ or Bslightly easy.^ No
participant reported the device was Bdifficult^ to use
in any way.
User Interface design validation study
Forty untrained adult (age ≥ 20 years) and juvenile (ages
12 to 19 years) participants were asked to take the nal-
oxone auto-injector without being exposed to the product
or any associated instructional leaflets/training and
administer an injection into a mannequin. Participants
were read the scenario and told that the study was de-
signed to simulate a Breal-life opioid emergency.^ Ninety
percent of participants were able to do so properly. Of
the 10 % of participants who failed to deliver the injec-
tion without any training, the use errors were failure to
press the device firmly enough to engage the injection
mechanism (n = 2), use of the trainer device instead of
the actual device (n = 1), and failure to hold the device
in place for one full second (n = 1).
The average time to complete the simulated injection from
selection of the device to completed injection was 64.0 s for
adults and 57.6 s for juveniles. When asked to rate the diffi-
culty of administering the injection, 70 % rated every step in
the process as Beasy^ or Bvery easy.^ Twenty percent rated
only one of the steps as Bhard^ and the rest as Beasy^ or Bvery
easy.^ Of the juvenile subjects, 10 % rated more than one of
the steps as Bhard.^ One area that challenged participants was
difficulty removing the safety guard, leading to some of the
lower ratings. However, one participant stated that the red
Table 2 Potential use errors for
the naloxone auto-injector identi-
fied as a part of Human Factors
Engineering and risk analyses
Severity Potential Use Errors
Minor User could misplace instructions, trainer device, or forget key steps
User drops device before or while removing the outer case
User does not understand how to open the package or has difficulty removing the packaging
User fails to hold the injector in place for the full five seconds
User ignores the instructional leaflet and uses the device anyway (untrained user)
User ignores the instructions on the device itself (untrained user)
User removes the safety guard prematurely and then tries to replace it
Moderate User moves device during the injection, leading to possibility of ineffective dose
User misplaces the device or cannot find it readily
User has difficulty pulling off the safety guard
User does not apply sufficient force initially to activate the injection then eventually determines
force required
User has difficulty removing the device from the outer case
User attempts to disassemble the device, causing the possibility of premature activation which
might result in unintentional self-injection
User removes the safety guard and then drops the device, causing the potential for premature
activation
Critical User employs the device but the drug is expired or degraded
User attempts to use a previously used device
User does not remove the red safety guard
User pulls the device away from the outer thigh prematurely or fails to hold the injector in place for
at least 0.5 s
User decides not to give the injection
User places the device in the wrong location (not on the outer thigh or an appropriate muscle)
User does not place the base on the outer thigh or appropriate alternate location
User never applies sufficient force to activate the injection
User puts hand over the wrong end, possibly resulting in accidental self-injection
User pushes the base with fingers causing premature activation
User uses the training device on the patient instead of the actual device containing drug
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safety guard should be somewhat difficult to remove since it is
a safety feature.
When asked if they would be confident using the device
again, all of the test participants (100 %) said they would.
Importantly, all participants stated that they would call for
emergency help either before or after using the auto-injector.
Participants were asked for their opinion about the voice
prompts. The majority (83 %) rated voice prompts as a posi-
tive feature and more than half (62.5 %) rated it as the first of
the device’s positive features. In a post-test risk assessment for
critical use errors, that is, errors that in a real-world situation
might have led to failure to administer naloxone properly,
90 % of participants would have been able to administer the
naloxone appropriately without training.
Comparative usability studies
Two randomized, controlled head-to-head usability studies
(one located in Pennsylvania and another in Massachusetts)
comparing the naloxone auto-injector to an improvised intra-
nasal (IN) naloxone delivery system were conducted to assess
correct administration of naloxone during a simulated opioid
emergency. The studies assessed participants’ ability to suc-
cessfully administer naloxone without training or exposure to
the product and associated instructional materials as well as
whether participants retained the ability to correctly adminis-
ter naloxone a week or more following training. The simula-
tion included a home environment scenario with distractions
added to induce stress to the environment and encompassed
three phases. In Phase I, each study participant was read a
scenario by the moderator reflecting a common opioid over-
dose emergency situation. Participants then needed to admin-
ister naloxone to a mannequin (randomly assigned face-up or
face-down) using the product found on a table in accordance
with its labeling with no other training or instructional mate-
rials provided. This approach was used to model a real life
scenario where a family member or caregiver of an opioid
overdose victim may need to administer naloxone without
any formal training or prior exposure to the naloxone delivery
system. Participants were randomly assigned to either nalox-
one auto-injector or the IN naloxone delivery system first and
the other naloxone product second to complete Phase I. Use of
a naloxone product was considered complete when the study
participant indicated that he/she had finished or upon 15 min
having elapsed during the participant’s attempt to use the nal-
oxone product. Phase II occurred immediately after Phase I
and involved training of each study participant on proper use
of the naloxone auto-injector and the IN naloxone delivery
system by a trained healthcare professional. Participants were
required to demonstrate correct use of both naloxone products
for Phase II completion. Study participants returned no sooner
than seven days later for Phase III. In Phase III, each study
participant repeated the simulated opioid overdose emergency
scenario from Phase I. Participants were required to recall the
training that was given during Phase II as no additional train-
ing or instructional materials were provided before or during
Phase III except for labeling on the naloxone products.
Successful administration was defined as whether the study
participant would have administered the intended dose of nal-
oxone. In phase 1, 94 % of participants could complete a
successful injection using the naloxone auto-injector versus
0.0 % of those using the IN naloxone delivery system
(p < 0.0001). In phase III, 100 % of participants completed a
successful injection using the naloxone auto-injector versus
50.6 % using the IN naloxone delivery system (p < 0.0001).
The average time for successful naloxone administration in
Phase I with the naloxone auto-injector was 56 s and an aver-
age time was not available for the IN naloxone delivery sys-
tem as no participants successfully administered the IN nalox-
one [35]. After excluding Phase III completion times for study
participants who were unsuccessful in administering naloxone
for any reason, study participants were able to successfully
administer naloxone 3 times faster with the naloxone auto-
injector (35 s) as compared to the IN naloxone system (88 s).
Discussion
Opioid emergencies, including overdose, are frequently
witnessed and many occur at home [36]. To our knowledge,
the concept of providing naloxone for the out-of-hospital ad-
ministration for opioid overdose emergencies was first pro-
posed in the literature in 1996 [37]. While much emphasis
has been placed on reducing overdose mortality among the
injection drug-using population and those using opioids non-
medically, the population of patients prescribed opioid anal-
gesics for control of chronic or cancer pain, including their
children, comprises the larger group at increased risk for an
opioid emergency [28]. These patients may benefit the most
from the novel auto-injector in that they are the more numer-
ous group and likely live with family and caregivers who can
be equipped with the auto-injector and trained in its proper
use. Prior emergency naloxone delivery models relied on IN
or IM dosing and required specific assembly or delivery steps
that were not always intuitive to inexperienced users. These
naloxone kits worked well with community groups who were
able to train volunteers to introduce the kits into the street drug
community but have limitations for the broader layperson
community.
Until the naloxone auto-injector, there was no FDA-
approved product that could be readily available and used in
the out-of-hospital setting by laypersons. Thus, this novel nal-
oxone product meets a large need in a particularly user-
friendly way. Analogous to an automated external defibrilla-
tor, the naloxone auto-injector is designed to be used by vir-
tually anyone: trained or untrained caregivers, family
8 Drug Deliv. and Transl. Res. (2017) 7:1–10
members, friends, bystanders, and others suddenly confronted
with a life-threatening opioid overdose emergency; and was
developed using a robust HFE process so that it is can be used
virtually anywhere: at home, in the office, while shopping or
traveling, indoors or outdoors. The auto-injector was carefully
designed to help mitigate situational aspects (e.g., use envi-
ronments, noise level) that could exacerbate the considerable
stress that could be experienced by the caregiver or bystander
during an opioid emergency. For that reason, testing of the
auto-injector was conducted under a variety of use conditions
(e.g., home use, distractions) and under a variety of simulated
weather conditions (e.g., cold weather, rain, heat, high humid-
ity). In all normal or even extreme conditions (e.g., between
the temperature range 4 °C and 40 °C), the device was verified
to function properly. This degree of versatility is an important
aspect to the utility of the auto-injector.
Prescribers must recognize that life-threatening opioid
emergencies characterized by OIRD are not rare events.
They affect patients as well as heroin users taking prescribed
opioid pain relievers under medical supervision. These emer-
gencies may also affect small children through accidental ex-
posure. In the event of an opioid overdose emergency, the
ability of a person on the scene, regardless of age, training,
or medical background, to administer an effective dose of
naloxone through the proven injectable route of administra-
tion, combined with an easy to use delivery system, has the
clear potential to save lives. As such, the naloxone auto-
injector could be a universal precaution for those who pre-
scribe opioid therapy. Family members or caregivers of the
opioid patient can be trained on the simple steps to deliver a
naloxone injection by using the Trainer for practice as sug-
gested in the product approved labeling. Even without train-
ing, studies have demonstrated that most people can correctly
administer naloxone using the auto-injector.
Conclusion
The increased use of opioids for chronic treatment of pain and the
resulting epidemic of opioid overdoses have created a major
public health challenge. Parenteral naloxone has been used for
over 40 years to treat opioid overdose. In 2014, FDA approved a
novel naloxone auto-injector device (EVZIO, kaleo, Inc.,
Richmond, VA) that can be prescribed for Btake-home^ use
and administered parenterally by laypeople. Since naloxonemust
be administered quickly, under highly stressful conditions, and
possibly by inexperienced laypeople, it was crucial to design and
develop a product that incorporated HFE, risk analyses, and ac-
tual testing of user-device interaction without training.
Developing a drug-device combination product requires a rigor-
ous development process that, in the case of the naloxone auto-
injector, involved more than 100 engineering verification tests,
multiple usability methodologies and studies. Applying a robust
development process incorporating HFE resulted in a product
that was designed to be safe, fast, easy and predictably reliable
to deliver a potentially life-saving dose of naloxone during an
opioid overdose emergency.
Acknowledgments This paper was prepared with editorial support
from Mark Elzey, MD, who is employed by kaleo, Inc., Richmond,
Virginia as well as LeQ Medical, Angleton, Texas, whose services were
paid for by the authors.
Compliance with ethical standards
Conflict of interest disclosure This paper was prepared by NEMA
Research Inc. medical writing staff. NEMA Research Inc. received
funding from kaleo, Inc. for the preparation of this manuscript. Dr.
Nalamachu and Dr. Pergolizzi are consultants for kaleo Inc. Dr. Raffa is
a consultant for NEMA Research. Dr. Taylor is an employee of NEMA
Research. Dr. Elzey and Dr. Edwards are employees of kaleo Inc.
References
1. Daher M. Pain relief is a human right. Asian Pacific J Cancer Prev :
APJCP. 2010;11(Suppl 1):97–101.
2. Volkow ND. Prescription Opioid and Heroin Abuse. National
Institute on Drug Abuse. https://www.drugabuse.gov/about-
nida/legislative-activities/testimony-to-congress/2015/prescription-
opioid-heroin-abuse. Accessed 3 Mar 2016. 2014.
3. Centers for Disease Control and Prevention. Trends in Drug-
Poisoning Deaths Involving Opioid Analgesics and Heroin:
United States, 1999 to 2012. In: NCHS Health E-Stat. Centers for
Disease Control and Prevention,, Atlanta, GA. http://www.cdc.
gov/nchs/data/hestat/drug_poisoning/drug_poisoning.htm.
Accessed 27 Jul 2015. 2014.
4. Centers for Disease Control and Prevention. QuickStats: Rates of
Deaths from Drug Poisoning and Drug Poisoning Involving Opioid
Analgesics-United States, 1999–2013. Morbidity and Mortality
Weekly Report. 2015;64(1):32.
5. Warner M, Chen L, Makuc D, Anderson R, Minino A. Drug poi-
soning deaths in the United States, 1980–2008. Hyattsville, MD:
National Center for Health Statistics 2011.
6. Manchikanti L, Helm 2nd S, Fellows B, Janata JW, Pampati V,
Grider JS, et al. Opioid epidemic in the United States. Pain Phys.
2012;15(3 Suppl):ES9–38.
7. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D,
et al. Patterns of abuse among unintentional pharmaceutical over-
dose fatalities. JAMA : J Am Med Assoc. 2008;300(22):2613–20.
doi:10.1001/jama.2008.802.
8. Paulozzi L. CDC: grand rounds: prescription drug overdoses-
A U.S. epidemic. Morb Mortal Wkly Rep. 2012;61(01):10–3.
9. Zedler B, Xie L, Wang L, Joyce A, Vick C, Kariburyo F, et al. Risk
factors for serious prescription opioid-related toxicity or overdose
among veterans health administration patients. Pain Med.
2014;15(11):1911–29.
10. Paulozzi LJ. Prescription drug overdoses: a review. J Saf Res.
2012;43(4):283–9. doi:10.1016/j.jsr.2012.08.009.
11. Yokell M, Delgardo M, Zaller N, Wang N, McGowan S, Green T.
Presentation of prescription and nonprescription opioid overdoes to
US emergency departments. JAMA Internal Med. 2014;174(12):
2034–7.
Drug Deliv. and Transl. Res. (2017) 7:1–10 9
12. Burghardt LC, Ayers JW, Brownstein JS, Bronstein AC, Ewald
MB, Bourgeois FT. Adult prescription drug use and pediatric med-
ication exposures and poisonings. Pediatrics. 2013;132(1):18–27.
doi:10.1542/peds.2012-2978.
13. Alliance FC. Hypoxic-Anoxic Brain Injury. 2004. https://www.
caregiver.org/hypoxic-anoxic-brain-injury. Accessed 3 Mar 2016.
14. Agamanol is DP. Cerebra l Ischemia and Stroke. In:
Neuropathology: An Illustrated Interactive Course for Medical
Students and Residents. 2013. http://neuropathology-web.
org/chapter2/chapter2aHIE.html. Accessed 6 Mar 2016.
15. The National Emergency Medical Services for Children Data Analysis
Resource Center. National EMS Information System (NEMSIS Data):
Average EMS Response Times, Scene Times, and Transport Times.
2012. http://www.nedarc.org/emsDataSystems/nemsisReports/2010_11
EMSTimes.html. Accessed 3 Mar 2016.
16. Green TC, Heimer R, Grau LE. Distinguishing signs of opioid
overdose and indication for naloxone: an evaluation of six overdose
training and naloxone distribution programs in the United States.
Addiction (Abingdon, England). 2008;103(6):979–89. doi:10.1111
/j.1360-0443.2008.02182.x.
17. Kim HK, Nelson LS. Reducing the harm of opioid overdose with the
safe use of naloxone : a pharmacologic review. Expert Opin Drug Saf.
2015;14(7):1137–46. doi:10.1517/14740338.2015.1037274.
18. Mueller SR, Walley AY, Calcaterra SL, Glanz JM, Binswanger IA. A
review of opioid overdose prevention and naloxone prescribing: impli-
cations for translating community programming into clinical practice.
Substance Abuse. 2015:1–14. doi:10.1080/08897077.2015.1010032.
19. Community Management of Opioid Overdose. Geneva: World
Health Organization. 2014.
20. Strang J, McDonald R, Tas B, Day E. Clinical provision of impro-
vised nasal naloxone without experimental testing and without reg-
ulatory approval: imaginative shortcut or dangerous bypass of es-
sential safety procedures? Addiction (Abingdon, England).
2016;111(4):574–82. doi:10.1111/add.13209.
21. Rowe C, Santos GM, Vittinghoff E, Wheeler E, Davidson P, Coffin
PO. Predictors of participant engagement and naloxone utilization
in a community-based naloxone distribution program. Addiction
(Abingdon, England). 2015. doi:10.1111/add.12961.
22. Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M,
Sorensen-Alawad A, et al. Opioid overdose rates and implementa-
tion of overdose education and nasal naloxone distribution in
Massachusetts: interrupted time series analysis. BMJ (Clin Res).
2013;346:f174. doi:10.1136/bmj.f174.
23. Project Lazarus. Community-based overdose prevention and opioid
safety with community care of North Carolina. Project Lazarus,
Moravian Falls, NC. 2015. http://www.projectlazarus.org//.
Accessed 27 Jul 2015.
24. Bennett AS, Bell A, Tomedi L, Hulsey EG, Kral AH.
Characteristics of an overdose prevention, response, and naloxone
distribution program in Pittsburgh and Allegheny County,
Pennsylvania. J Urban Health : Bull N YAcad Med. 2011;88(6):
1020–30. doi:10.1007/s11524-011-9600-7.
25. Robinson A,Wermeling DP. Intranasal naloxone administration for
treatment of opioid overdose. Am JHealth-Syst Pharm : AJHP : Off
J Am Soc Health-Syst Pharm. 2014;71(24):2129–35. doi:10.2146
/ajhp130798.
26. Kerr DR, Kelly A-M, Dietze P, Jolley D, Barger B. Randomized
controlled trial comparing the effectiveness and safety of intranasal
and intramuscular naloxone for the treatment of suspected heroin
overdose. Addiction (Abingdon, England). 2009;104(12):2067–74.
27. Kelly AM, Kerr DR, Dietze P, Patrick I,Walker T, Koutsogiannis Z.
Randomised trial of intranasal versus intramuscular naloxone in
prehospital treatment for suspected opioid overdose. Med J Aust.
2005;181(1):24–7.
28. Centers for Disease C, Prevention. CDC grand rounds: prescription
drug overdoses - a U.S. epidemic.MMWRMorbMortalWkly Rep.
2012;61(1):10–3.
29. Wheeler E, Jones TS, Gilbert MK, Davidson PJ. Opioid overdose
prevention programs providing naloxone to laypersons - United
States, 2014.MMWRMorbMortalWkly Rep. 2015;64(23):631–5.
30. FDA. Medical Devices; Current Good Manufacturing Practice
(CGMP) Final Rule; Quality System Regulation. Food and Drug




31. Food and Drug Administration. Applying Human Factors and
Usability Engineering to Medical Devices: Guidance for Industry
and Food and Drug Administration Staff In: Center for Devices and
Radiological Health, editor. 2016.
32. Story M. FDA Human Factors Draft Guidance Document: Agency
Expectations for Human Factors Data in Premarket Submission.
Rockville, MD: US Food and Drug Administration; 2012. p. 22
May.
33. Edwards E, Edwards E, Simons F, North R. Drug-device combina-
tion products in the twenty-first century: epinephrine auto-injector
development using human factors engineering. Expert Opin Drug
Deliv. 2015;12(5):751–62.
34. Wermeling DP. Review of naloxone safety for opioid overdose:
practical considerations for new technology and expanded public
access. Ther Adv Drug Saf. 2015;6(1):20–31. doi:10.1177
/2042098614564776.
35. Edwards ET, Edwards ES, Davis E,MulcareM,WiklundM,Kelley
G. Comparative usability study of a novel auto-injector and an
intranasal system for naloxone delivery. Pain Ther. 2015.
doi:10.1007/s40122-015-0035-9.
36. Sporer KA. Acute heroin overdose. Ann Intern Med. 1999;130(7):
584–90.
37. Strang J, Darke S, Hall W, Farrell M, Alt R. Heroin overdose: the
caes for take-home naloxone. BMJ (Clin Res). 1996;312:1435–6.
10 Drug Deliv. and Transl. Res. (2017) 7:1–10
